NCT00050687View on ClinicalTrials.gov

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

PHASE1/PHASE2TerminatedINTERVENTIONAL
Timeline

Start Date

June 30, 2001

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
Prostatic NeoplasmsMultiple MyelomaBladder NeoplasmsLymphoma
Interventions
DRUG

Gallium maltolate

Trial Locations (5)

10021

New York Presbyterian Hospital, New York

48076

Southfield Oncology Institute, Southfield

72764

Highlands Oncology Group, PA, Springdale

94303

Stanford University, Palo Alto

94904

California Cancer Care, Greenbrae

Sponsors
All Listed Sponsors
lead

Titan Pharmaceuticals

INDUSTRY

NCT00050687 - Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | Biotech Hunter | Biotech Hunter